CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
E4512 ECOG A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Adult CIRB - Late Phase Emphasis
E4599 ECOG Randomized Phase II/III Trial of Paclitaxel plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients with Advanced Nonsquamous NSCLC Adult CIRB - Late Phase Emphasis
E4A03 ECOG A Randomized Phase III Study of CC-5013 Plus Dexamethasone Versus CC-5013 Plus Low Dose Dexamethasone in Multiple Myeloma with Thalidomide Plus Dexamethasone Salvage Therapy for Non-Responders Adult CIRB - Late Phase Emphasis
E4A08 ECOG A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) versus Bortezomib; Melphalan; and Dexamethasone (BMDex) for Untreated Patients with Systemic Light-chain (AL) Amyloidosis Ineligible for Autologous Stem-cell Transplantation Adult CIRB - Late Phase Emphasis
E5103 ECOG A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer Adult CIRB - Late Phase Emphasis
E5202 ECOG A Randomized Phase III Study Comparing 5-FU; Leucovorin and Oxaliplatin Versus 5-FU; Leucovorin; Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Adult CIRB - Late Phase Emphasis
E5204 ECOG Intergroup Randomized Phase III Study of Postoperative Oxaliplatin; 5-Fluorouracil; and Leucovorin vs Oxaliplatin; 5-Fluorouracil; Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation Adult CIRB - Late Phase Emphasis
E5508 ECOG Randomized Phase III Study of Maintenance Therapy with Bevacizumab; Pemetrexed; or a Combination of Bevacizumab and Pemetrexed Following Carboplatin; Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC Adult CIRB - Late Phase Emphasis
E6201 ECOG A Phase III; Randomized Study of Gemcitabine [fixed-dose rate infusion] and Oxaliplatin (NSC 266046) versus Gemcitabine [fixed-dose rate infusion] versus Gemcitabine [30-minute infusion] in Pancreatic Carcinoma Adult CIRB - Late Phase Emphasis
EA1131 ECOG-ACRIN A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoadjuvant Chemotherapy Adult CIRB - Late Phase Emphasis